Home › Merck Statement on FDA Advisory Committee Meeting on IMPROVE-IT Study with VYTORIN (ezetimibe and simvastatin)
 

Keywords :   


Merck Statement on FDA Advisory Committee Meeting on IMPROVE-IT Study with VYTORIN (ezetimibe and simvastatin)

2015-12-15 00:23:15| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, issued today the following statement after the conclusion of a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) to discuss the results of IMPROVE-IT, an investigational study comparing treatment with VYTORIN (ezetimibe and simvastatin) to treatment with simvastatin alone in more than 18,000 patients presenting with acute coronary syndromes. Language: English read more

Tags: statement study meeting committee

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.05Reddit shares jump after OpenAI ChatGPT deal
17.05Is China's bubble tea bubble about to burst?
17.05Eastern North Pacific Tropical Weather Outlook
17.05Atlantic Tropical Weather Outlook
17.05Business locked in expensive AI 'arms race'
17.05Is the move to electric cars running out of power?
17.05Pornhub partners with UK child abuse fighting charity
17.05Pornhub partners with UK child abuse fighting charity
More »